Skip to content

Studying cancer patients taking homoeopathic treatment along with existing treatment.

Studying The Change In The Susceptibility In Patients With Cancer Through Indicated Homoeopathic Remedy As Add-On Existing Treatment: An Uncontrolled Experimental Study. - Nil.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/102219
Enrollment
50
Registered
2026-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Indicated Homoeopathic remedy.: Indicated Homoeopathic remedy will be prescribed at a minimum of one dose of 6-8 pills orally in 30 or 200 or LM potencies every week, as per the totalit

Sponsors

Dept Of Organon and Homoeopathic Philosophy, Dr M.L. Dhawale Memorial Institute, and trust.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of cancer with biopsy or available investigations. The cases must have appropriate data recorded in Standardised Case Record format. Cases of all stages and type of cancers. All cases of cancers willing to be part of the study and who are ready to take homoeopathy as an adjuvant to the conventional treatment. All cases where patients are taking homoeopathy and the changes in susceptibility can be assessed under supervision of senior homoeopathic consultant.

Exclusion criteria

Exclusion criteria: Patients who are not willing to be part of the study. Patients not willing to give their data for observation and assessment for this study.

Design outcomes

Primary

MeasureTime frame
The change in the susceptibility score of the patient, measured using the newly developed Susceptibility Assessment Scale at baseline and at specific follow-up [4weekly] intervals until 48 weeks during the 24-month study period. Timepoint: baseline of week 0, week 4 ... maximum until week 48.

Secondary

MeasureTime frame
Evaluation of clinical improvement in patient-reported symptoms and general well-being as an add-on effect to conventional therapy using MYMOP2Timepoint: Baseline or week 0, week 4, maximum until week 48.

Countries

India

Contacts

Public ContactDr Anand Kapse

Dr M.L. Dhawale Memorial Institute Palghar,

arkapse@gmail.com9371721780

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026